MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Country |
 USA |
IPO year |
- |
Industry |
Diagnostics research |
Stock Exchange |
NYSESPB |
Shares |
377 M |
Market Cap[1] |
$ 180 B |
EBITDA (LTM) |
$ 8.38 B |
P/E (LTM) |
28.22 |
P/S (LTM) |
4.17 |
EPS (LTM) |
16.81 |
Thermo Fisher Scientific is a globally leading company in the life science industry, focusing on the development and manufacturing of products and services for research, diagnostics, and drug production. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
Thermo Fisher Scientific offers a wide range of products, including laboratory equipment, reagents, consumables, software, and services. The company serves customers in the pharmaceutical and biotech, diagnostics, academic research, and government sectors.
The mission of Thermo Fisher Scientific is to help its customers make the world healthier, cleaner, and safer. The company is also committed to sustainability and aims to reduce its greenhouse gas emissions by 50% by 2030.
Thermo Fisher Scientific is known for its innovation and has received numerous awards for its products and technologies. The company has also made several acquisitions to expand its product offerings and strengthen its presence in different regions.
Overall, is a leading company in the life science industry that is committed to innovation, sustainability, and customer satisfaction. Its products and services have a positive impact on the health and well-being of people around the world.
Other stocks of industry "Diagnostics research"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | Nasdaq Global Market |  Germany |
 |
Interpace Biosciences
IDXG
|
$ 1.71 | 0.73 % | $ 7.5 M | Nasdaq Global Select Market | USA |
 |
Illumina
ILMN
|
$ 123.79 | -0.43 % | $ 19.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Biomerica
BMRA
|
$ 2.13 | -2.74 % | $ 4.89 M | Nasdaq Capital Market | USA |
 |
Castle Biosciences
CSTL
|
$ 25.75 | 3.0 % | $ 715 M | Nasdaq Global Market,SPB | USA |
 |
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | Nasdaq Capital Market |  Israel |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | Nasdaq Capital Market |  Canada |
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | NYSE | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Nasdaq Global Select Market |  Britain |
 |
NeoGenomics
NEO
|
$ 8.1 | 1.76 % | $ 1.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Exact Sciences Corporation
EXAS
|
$ 104.91 | - | $ 19.8 B | Nasdaq Capital Market,SPB | USA |
 |
National Research Corporation
NRC
|
$ 17.51 | 1.1 % | $ 392 M | Nasdaq Global Select Market | USA |
 |
Natera
NTRA
|
$ 200.09 | 2.46 % | $ 19.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | Nasdaq Capital Market,SPB | USA |
 |
Co-Diagnostics
CODX
|
$ 4.4 | 101.83 % | $ 129 M | Nasdaq Capital Market | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | Nasdaq Global Select Market | USA |
 |
OPKO Health
OPK
|
$ 1.15 | 2.68 % | $ 798 M | Nasdaq Global Select Market | USA |
 |
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | NYSE |  China |
 |
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | Nasdaq Global Select Market | USA |
 |
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | Nasdaq Capital Market |  Australia |
 |
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | Nasdaq Global Market | China |
 |
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | Nasdaq Global Select Market | USA |
 |
Personalis
PSNL
|
$ 7.61 | 4.82 % | $ 451 M | Nasdaq Global Select Market | USA |
 |
Charles River Laboratories International
CRL
|
$ 158.0 | 2.86 % | $ 7.83 B | NYSE,SPB | USA |
 |
IQVIA Holdings
IQV
|
$ 166.96 | 0.54 % | $ 28.7 B | NYSE,SPB | USA |
 |
Lantheus Holdings
LNTH
|
$ 75.73 | -0.92 % | $ 5.11 B | Nasdaq Global Select Market,SPB | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Nasdaq Global Select Market | Israel |
 |
IDEXX Laboratories
IDXX
|
$ 578.51 | 0.22 % | $ 46.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | Nasdaq Capital Market | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | NYSE,SPB | USA |
 |
BioNano Genomics
BNGO
|
$ 1.46 | 26.96 % | $ 1.86 M | Nasdaq Capital Market,SPB | USA |
 |
Medpace Holdings
MEDP
|
$ 456.93 | 0.98 % | $ 13.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Senseonics Holdings
SENS
|
$ 6.62 | 2.16 % | $ 276 M | NYSE American | USA |
 |
Sotera Health Company
SHC
|
$ 13.88 | 2.81 % | $ 3.94 B | Nasdaq Global Select Market | USA |
 |
Agilent Technologies
A
|
$ 112.02 | 0.65 % | $ 34.1 B | NYSE,SPB | USA |
 |
ICON Public Limited Company
ICLR
|
$ 100.35 | 0.65 % | $ 8.28 B | Nasdaq Global Select Market,SPB |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
$ 31.72 | -4.52 % | $ 1.61 B | Nasdaq Capital Market | USA |
 |
DarioHealth Corp.
DRIO
|
$ 7.5 | -6.13 % | $ 29.9 M | Nasdaq Capital Market | Israel |
 |
Guardant Health
GH
|
$ 84.9 | -0.33 % | $ 10.6 B | Nasdaq Global Select Market,SPB | USA |
 |
Myriad Genetics
MYGN
|
$ 4.66 | 1.75 % | $ 432 M | Nasdaq Global Select Market,SPB | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | Nasdaq Global Select Market | USA |
 |
Neuronetics
STIM
|
$ 1.6 | 10.34 % | $ 106 M | Nasdaq Global Select Market | USA |
 |
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | NYSE |  Niderland |
 |
Mettler-Toledo International
MTD
|
$ 1 239.07 | 2.87 % | $ 25.5 B | NYSE,SPB |  Schweiz |
 |
CareDx, Inc
CDNA
|
$ 17.56 | 2.39 % | $ 936 M | Nasdaq Global Market,SPB | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 3.48 | 0.87 % | $ 1.87 M | Nasdaq Global Select Market | USA |
 |
Celcuity
CELC
|
$ 106.75 | 0.67 % | $ 4.21 B | Nasdaq Global Select Market | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | Nasdaq Capital Market | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 264.42 | 0.54 % | $ 22 B | NYSE,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.